Assessed for eligibility (N=66)

Randomized (n=48)

Arm A: motesanib 125 mg QD (n=25*)
  - Received motesanib (n=25)

Discontinued treatment (n=25)
  - Disease progression (n=18)
  - Adverse event (n=5)
  - Continuing treatment in rollover study† (n=2)
  - Consent withdrawn (n=0)

Gallbladder analysis set, ultrasound (n=23)
  - Excluded (n=2)
Gallbladder analysis set, CCK-HIDA (n=22)
  - Excluded (n=3)
Safety analysis set (n=25)

Arm B: motesanib 75 mg BID, 14 d on/7 d off (n=12)
  - Received motesanib (n=12)

Discontinued treatment (n=12)
  - Disease progression (n=9)
  - Adverse event (n=2)
  - Continuing treatment in rollover study† (n=1)
  - Consent withdrawn (n=0)

Gallbladder analysis set, ultrasound (n=11)
  - Excluded (n=1)
Gallbladder analysis set, CCK-HIDA (n=10)
  - Excluded (n=2)
Safety analysis set (n=12)

Arm C: motesanib 75 mg BID, 5 d on/2 d off (n=12)
  - Received motesanib (n=12)

Discontinued treatment (n=12)
  - Disease progression (n=5)
  - Adverse event (n=4)
  - Continuing treatment in rollover study† (n=2)
  - Consent withdrawn (n=1)

Gallbladder analysis set, ultrasound (n=11)
  - Excluded (n=1)
Gallbladder analysis set, CCK-HIDA (n=10)
  - Excluded (n=2)
Safety analysis set (n=12)